All In Biotech

Drug Trial Radar · NCT05667454

MAD Trial: Myopia Atropine Dose

Investigator Led, Double-masked, Multicenter, Randomized Clinical Trial for the Comparison of Atropine 0.5% Versus Atropine 0.05% Eye Drops for the Prevention of Myopia Progression in Dutch Children

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Dec 19, 2022

Primary completion

Apr 24, 2029

Study completion Apr 24, 2029

Sponsor

Lead sponsor
Erasmus Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
First posted
Dec 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional study is to compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment against progression of axial length in European children with progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse. Subjects will use Atropine eye drops for a period of 3 years, followed by a 2 year observational period.

Conditions

  • Progressive Myopia

Interventions

  • Atropine Ophthalmic 0.05%Drug

    Atropine 0.05% sulphate ophthalmic solution

  • Atropine Ophthalmic 0.5%Drug

    Atropine 0.5% sulphate ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression of axial length in mm from baseline to t = 36 months.Time frame: 3 years

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Flevoziekenhuis

    Almere Stad, Netherlands

  • OLVG, locatie Oost

    Amsterdam, Netherlands

  • Ophthalmologistenpraktijk Delfland

    Delft, Netherlands

  • Reinier de Graaf Gasthuis

    Delft, Netherlands

  • Deventer Ziekenhuis

    Deventer, Netherlands

  • Albert Schweitzer ziekenhuis

    Dordrecht, Netherlands

  • Bergman Clinics - Ede

    Ede, Netherlands

  • Admiraal de Ruyter Ziekenhuis

    Goes, Netherlands

  • Frisius MC

    Heerenveen, Netherlands

  • Oogcentrum Noordholland

    Heerhugowaard, Netherlands

  • Leiden University Medical Center

    Leiden, Netherlands

  • Bergman Clinics - Lelystad

    Lelystad, Netherlands

  • Maastricht UMC+

    Maastricht, Netherlands

  • St. Antonius

    Nieuwegein, Netherlands

  • Radboudumc

    Nijmegen, Netherlands

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • Haga Ziekenhuis

    The Hague, Netherlands

  • Oogkliniek Den Haag

    The Hague, Netherlands

  • Ziekenhuis Rivierenland Tiel

    Tiel, Netherlands

  • Elisabeth-TweeSteden Ziekenhuis

    Tilburg, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.